Litcius/Paper detail

Pharmacist-led counselling intervention to improve antiretroviral drug adherence in Pakistan: a randomized controlled trial

Zeenat Fatima Chatha, Usman Rashid, Sharon Olsen, Fakhar ud Din, Amjad Khan, Komal Nawaz, Siew Hua Gan, Gul Majid Khan

2020BMC Infectious Diseases20 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Pakistan is facing a growing population of people living with human immunodeficiency (HIV). In this randomized controlled trial, we investigate if a pharmacist-led intervention can increase adherence to antiretroviral therapy (ART) for people living with HIV (PLWH). METHODS: Adults with HIV, who have been taking ART for more than 3 months were randomly assigned to receive either a pharmacist-led intervention or their usual care. Measures of adherence were collected at 1) baseline 2) just prior to delivery of intervention and 3) 8 weeks later. The primary outcomes were CD4 cell count and self-reported adherence measured with the AIDS Clinical Trial Group (ACTG) questionnaire. RESULTS: Post-intervention, the intervention group showed a statistically significant increase in CD4 cell counts as compared to the usual care group (p = 0.0054). In addition, adherence improved in the intervention group, with participants being 5.96 times more likely to report having not missed their medication for longer periods of time (p = 0.0086) while participants in the intervention group were 7.74 times more likely to report missing their ART less frequently (p < 0.0001). CONCLUSIONS: The findings support the improvement in ART adherence and HIV management. TRIAL REGISTRATION: The trial is registered with Australian New Zealand Clinical Trials Registry ( ACTRN12618001882213 ). Registered 20 November 2018.

Topics & Concepts

MedicineRandomized controlled trialIntervention (counseling)Clinical trialPopulationPharmacistHuman immunodeficiency virus (HIV)Physical therapyFamily medicineInternal medicinePharmacyPsychiatryEnvironmental healthHIV/AIDS Research and InterventionsHIV-related health complications and treatmentsHIV/AIDS drug development and treatment